Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 24 | 17 | +0,22 % | ||
| AMGEN | 10 | 27 | -1,92 % | ||
| BIOGEN | 4 | 54 | -3,28 % | ||
| BIONTECH | 4 | 13 | -0,38 % | ||
| IMMUNITYBIO | 4 | 3 | +1,01 % | ||
| IDEAYA BIOSCIENCES | 3 | 3 | -1,41 % | ||
| BIOCRYST PHARMACEUTICALS | 3 | - | +5,88 % | ||
| DENALI THERAPEUTICS | 3 | - | -5,20 % | ||
| QUANTUM-SI | 3 | - | 0,00 % | ||
| SUMMIT THERAPEUTICS | 2 | 12 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:15 | Dividendenbekanntmachungen (07.04.2026) | 580 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) CAIXABANK SA ES0140609019 - 0,3321 EUR EDISON INTERNATIONAL US2810201077 0,8775 USD 0,7602 EUR ERIE INDEMNITY COMPANY US29530P1021 1... ► Artikel lesen | |
| 10:06 | TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition | 2 | Investing.com | ||
| 09:58 | Übernahme durch Neurocrine: TD Cowen stuft Soleno Therapeutics ab | - | Investing.com Deutsch | ||
| 09:36 | Sanofi's lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials | 16 | Seeking Alpha | ||
| 09:06 | Depression und PTBS im Fokus: Wie Emyria und AtaiBeckley neue Wirtschaftsmodelle in der Psychiatrie prägen | Small- & Micro Cap Investment | |||
| 08:19 | MESOBLAST LIMITED: Proposed issue of securities - MSB | - | ASX | ||
| 08:05 | Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today | 2 | The Motley Fool Australia | ||
| 07:46 | Sanofi meldet Studienerfolg mit Lunsekimig bei Asthma und Nasenpolypen | 12 | Investing.com Deutsch | ||
| 07:42 | Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies | 206 | AFX News | PARIS (dpa-AFX) - Sanofi (SNY, SAN.PA) said phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. In both studies... ► Artikel lesen | |
| 07:18 | Sanofi's lunsekimig meets goals in asthma, nasal polyps studies | 6 | Investing.com | ||
| 07:06 | Sanofi: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP | 15 | GlobeNewswire (Europe) | Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe... ► Artikel lesen | |
| 04:35 | Mesoblast shares are back in the red on Tuesday. Here's why | 4 | The Motley Fool Australia | ||
| 03:26 | Mesoblast's Ryoncil Achieves US$30.3 Million in Net Sales for March Quarter | 5 | Finance News Network | ||
| 03:06 | Mesoblast Limited: Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter | 10 | GlobeNewswire (Europe) | Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global... ► Artikel lesen | |
| 03:05 | Mesoblast shares: Ryoncil underpins strong earnings growth | 3 | The Motley Fool Australia | ||
| 02:27 | Why Biogen Stock Got Mashed on Monday | 3 | The Motley Fool | ||
| 02:27 | Why ImmunityBio Stock Slumped on Monday | 5 | The Motley Fool | ||
| 01:12 | MESOBLAST LIMITED: Ryoncil Net Revenue for the Quarter Increases to US$30.3M | 1 | ASX | ||
| 00:26 | Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects | 4 | Insider Monkey | ||
| 00:26 | CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment | 3 | Insider Monkey |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.